AMLX
Price
$13.86
Change
+$0.34 (+2.51%)
Updated
Jan 16, 11:07 AM (EDT)
Capitalization
1.48B
75 days until earnings call
Intraday BUY SELL Signals
SVRA
Price
$5.83
Change
-$0.05 (-0.85%)
Updated
Jan 16, 11:55 AM (EDT)
Capitalization
1.2B
69 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

AMLX vs SVRA

Header iconAMLX vs SVRA Comparison
Open Charts AMLX vs SVRABanner chart's image
Amylyx Pharmaceuticals
Price$13.86
Change+$0.34 (+2.51%)
Volume$680
Capitalization1.48B
Savara
Price$5.83
Change-$0.05 (-0.85%)
Volume$200
Capitalization1.2B
AMLX vs SVRA Comparison Chart in %
AMLX
Daily Signal:
Gain/Loss:
SVRA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
AMLX vs. SVRA commentary
Jan 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMLX is a Hold and SVRA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 16, 2026
Stock price -- (AMLX: $13.52 vs. SVRA: $5.88)
Brand notoriety: AMLX and SVRA are both not notable
AMLX represents the Pharmaceuticals: Generic, while SVRA is part of the Biotechnology industry
Current volume relative to the 65-day Moving Average: AMLX: 156% vs. SVRA: 63%
Market capitalization -- AMLX: $1.48B vs. SVRA: $1.2B
AMLX [@Pharmaceuticals: Generic] is valued at $1.48B. SVRA’s [@Biotechnology] market capitalization is $1.2B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $64.3B to $0. The market cap for tickers in the [@Biotechnology] industry ranges from $111.36B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.57B. The average market capitalization across the [@Biotechnology] industry is $2.26B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMLX’s FA Score shows that 0 FA rating(s) are green whileSVRA’s FA Score has 0 green FA rating(s).

  • AMLX’s FA Score: 0 green, 5 red.
  • SVRA’s FA Score: 0 green, 5 red.
According to our system of comparison, SVRA is a better buy in the long-term than AMLX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMLX’s TA Score shows that 4 TA indicator(s) are bullish while SVRA’s TA Score has 3 bullish TA indicator(s).

  • AMLX’s TA Score: 4 bullish, 6 bearish.
  • SVRA’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both AMLX and SVRA are a bad buy in the short-term.

Price Growth

AMLX (@Pharmaceuticals: Generic) experienced а +14.29% price change this week, while SVRA (@Biotechnology) price change was +2.08% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.62%. For the same industry, the average monthly price growth was +6.92%, and the average quarterly price growth was +19.07%.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.20%. For the same industry, the average monthly price growth was +4.47%, and the average quarterly price growth was +43.25%.

Reported Earning Dates

AMLX is expected to report earnings on Apr 01, 2026.

SVRA is expected to report earnings on Mar 26, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.62% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Biotechnology (+0.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AMLX($1.49B) has a higher market cap than SVRA($1.2B). AMLX YTD gains are higher at: 11.921 vs. SVRA (-2.488). SVRA has higher annual earnings (EBITDA): -120.38M vs. AMLX (-156.76M). AMLX has more cash in the bank: 344M vs. SVRA (124M). AMLX has less debt than SVRA: AMLX (5.94M) vs SVRA (29.8M). SVRA has higher revenues than AMLX: SVRA (0) vs AMLX (-665K).
AMLXSVRAAMLX / SVRA
Capitalization1.49B1.2B124%
EBITDA-156.76M-120.38M130%
Gain YTD11.921-2.488-479%
P/E Ratio2.69N/A-
Revenue-665K0-
Total Cash344M124M277%
Total Debt5.94M29.8M20%
FUNDAMENTALS RATINGS
SVRA: Fundamental Ratings
SVRA
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
PROFIT vs RISK RATING
1..100
39
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
36
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AMLXSVRA
RSI
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 12 days ago
81%
Bearish Trend 15 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
73%
View a ticker or compare two or three
Interact to see
Advertisement
AMLX
Daily Signal:
Gain/Loss:
SVRA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BWLAX25.630.14
+0.55%
American Beacon Man Lg Cp Value A
DEMZX34.530.16
+0.47%
Nomura Emerging Markets R6
AIAGX10.570.02
+0.19%
abrdn Real Estate Fund A
FCCVX37.70N/A
N/A
Fidelity Advisor Convertible Secs C
FLUAX29.57N/A
N/A
Fidelity Advisor Stk Selec Lg Cp Val A

AMLX and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMLX has been closely correlated with XOMAO. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if AMLX jumps, then XOMAO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMLX
1D Price
Change %
AMLX100%
-3.91%
XOMAO - AMLX
68%
Closely correlated
-0.24%
XOMAP - AMLX
51%
Loosely correlated
N/A
OCUL - AMLX
46%
Loosely correlated
+1.90%
LRMR - AMLX
45%
Loosely correlated
-4.40%
RGNX - AMLX
43%
Loosely correlated
-7.96%
More

SVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, SVRA has been loosely correlated with RCKT. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if SVRA jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SVRA
1D Price
Change %
SVRA100%
-2.00%
RCKT - SVRA
60%
Loosely correlated
-6.31%
PRTA - SVRA
49%
Loosely correlated
+0.65%
RGNX - SVRA
36%
Loosely correlated
-7.96%
AMLX - SVRA
36%
Loosely correlated
-3.91%
OCUL - SVRA
36%
Loosely correlated
+1.90%
More